clinical trial · NCT06256588
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
GlaxoSmithKline·phase3·recruiting·n = 864
Neoplasms, Head and NeckDostarlimabPlacebo
brief summary
The goal of this study is to assess the safety and effectiveness of Dostarlimab compared to Placebo in adult participants with Head and Neck Squamous Cell Carcinoma (HNSCC)
started
Mar 21, 2024
primary completion
Jun 30, 2028
completion
Oct 26, 2029
last updated
Sep 25, 2025
official title
A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate Dostarlimab as Sequential Therapy After Chemoradiation in Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol